Cross-sectional Evaluation of clinical symptoms and epidemiologic parameters in patients with TMA, differentiated by laboratory param-eters (CESAR)

Cross-sectional Evaluation of clinical symptoms and epidemiologic parameters in patients with TMA, differentiated by laboratory param-eters (CESAR) - CESAR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00006083

Enrollment

300

Registered

2014-04-23

Start date

2014-04-25

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D59.3 M31.1

Interventions

Group 1: evaluation of routine blood and stool diagnostic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. microangiopathic hemolytic anaemia, 2. thrombocytopenia: thrombocytes < 150 x 10´`9/l or thrombocytes decreased by more than 25% during one week, 3. One of the following: neurological symptoms, renal dysfunction, gastrointestinal symptoms

Exclusion criteria

Exclusion criteria: plasma intervention before blood sampling, antibiotic therapy before stool sampling

Design outcomes

Primary

Measure	Time frame
relative incidence of STEC-HUS (hemolytic uremic syndrome caused by Shigatoxin-producing E.coli serotypes), aHUS (atypical hemolytic uremic syndrome), and TTP (thrombotic thrombocytopenic purpura) through measuring ADAMTS13 activity and screening for shigatoxin-producing bacteria and shigatoxin.	—

Secondary

Measure	Time frame
comparison clinical symptoms and routine blood parameter for TTP, aHUS and STEC-HUS.	—

Countries

Germany

Contacts

Public ContactMichael Jeglitsch

Alexion Pharma Germany GmbH

Michael.Jeglitsch@alexion.com+49 89 /457091399

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026